^
    Back
    Association details:
    Biomarker:PTEN deletion
    Cancer:Chordoma
    Drug Class:PDGFR inhibitor +
    HDAC inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    PLoS One
    Title:

    Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma

    Excerpt:
    Combined PDGFR and HDAC inhibition is associated with reduction in invasion and proliferation...Chordoma cells with intact PTEN expression and those deficient for PTEN both demonstrate greater potential therapeutic response to the combination of PDGFR inhibitor and HDAC inhibition. The benefit of combined inhibition was particularly significant for attenuation of invasion.
    DOI:
    10.1371/journal.pone.0134426